Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$22.58
+5.1%
$22.06
$14.68
$28.35
$3.68B0.861.81 million shs3.67 million shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$226.96
-0.7%
$192.62
$97.50
$230.40
$14.34B0.27997,490 shs1.13 million shs
Perrigo Company plc stock logo
PRGO
Perrigo
$11.74
-4.3%
$10.99
$9.23
$28.43
$1.69B0.522.21 million shs2.70 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.45
-0.1%
$13.72
$12.77
$16.17
$11.23B0.272.61 million shs3.14 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+5.10%+0.56%+2.20%-4.18%+52.69%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-0.70%+11.79%+18.86%+37.14%+123.74%
Perrigo Company plc stock logo
PRGO
Perrigo
-4.39%-0.91%+11.33%-19.95%-55.43%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.12%-1.59%+3.62%-4.51%-0.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$22.58
+5.1%
$22.06
$14.68
$28.35
$3.68B0.861.81 million shs3.67 million shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$226.96
-0.7%
$192.62
$97.50
$230.40
$14.34B0.27997,490 shs1.13 million shs
Perrigo Company plc stock logo
PRGO
Perrigo
$11.74
-4.3%
$10.99
$9.23
$28.43
$1.69B0.522.21 million shs2.70 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.45
-0.1%
$13.72
$12.77
$16.17
$11.23B0.272.61 million shs3.14 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
+5.10%+0.56%+2.20%-4.18%+52.69%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-0.70%+11.79%+18.86%+37.14%+123.74%
Perrigo Company plc stock logo
PRGO
Perrigo
-4.39%-0.91%+11.33%-19.95%-55.43%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.12%-1.59%+3.62%-4.51%-0.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.75
Moderate Buy$31.2138.25% Upside
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2.83
Moderate Buy$230.561.59% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.00
Hold$19.3364.75% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00
Hold$16.9025.70% Upside

Current Analyst Ratings Breakdown

Latest ACAD, PRGO, RDY, and JAZZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Reiterated RatingOverweight$245.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Reiterated RatingOutperform$239.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetBuy$220.00 ➝ $275.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Set Price Target$252.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetOverweight$225.00 ➝ $234.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetOutperform$195.00 ➝ $258.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetOverweight$250.00 ➝ $265.00
5/1/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
DowngradeHold (C+)Hold (C)
4/29/2026
Perrigo Company plc stock logo
PRGO
Perrigo
DowngradeSell (D-)Sell (E+)
4/27/2026
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
UpgradeHold (C)Hold (C+)
4/27/2026
Perrigo Company plc stock logo
PRGO
Perrigo
UpgradeStrong SellHold
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B3.61$0.93 per share24.21$7.25 per share3.11
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.27B3.34$16.14 per share14.06$72.24 per share3.14
Perrigo Company plc stock logo
PRGO
Perrigo
$4.25B0.38$5.06 per share2.32$18.15 per share0.65
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B2.94$1.03 per share13.03$4.73 per share2.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2910.2625.6522.4034.30%10.23%7.37%N/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-$356.15M-$0.02N/A10.240.400.66%14.56%5.25%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$1.43B-$10.28N/A4.931.45-43.50%9.96%3.90%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.7717.4623.1820.9116.41%15.89%10.73%5/12/2026 (Estimated)

Latest ACAD, PRGO, RDY, and JAZZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q4 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.09N/AN/AN/A$886.58 millionN/A
5/6/2026Q1 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.04$0.02-$0.02$0.02$280.25 million$268.10 million
5/6/2026Q1 2026
Perrigo Company plc stock logo
PRGO
Perrigo
$0.39$0.43+$0.04-$2.87$1.04 billion$841.80 million
5/5/2026Q1 2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.67$6.34+$1.67$4.43$978.46 million$974.98 million
3/31/2026Q1 2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/A$6.34N/A$4.43N/A$1.07 billion
2/26/2026Q4 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.12$1.60+$1.48$1.60$292.54 million$298.00 million
2/26/2026Q4 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.80$0.77-$0.03-$10.22$1.09 billion$1.11 billion
2/25/2026Q4 2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$6.49$6.64+$0.15$3.21$1.17 billion$1.20 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.169.88%+5.21%N/A 23 Years
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.070.52%+9.86%9.09%N/A

Latest ACAD, PRGO, RDY, and JAZZ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.2910.29%5/29/20265/29/20266/16/2026
2/19/2026
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.299.36%3/2/20263/2/20263/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.83
3.71
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.95
2.04
1.67
Perrigo Company plc stock logo
PRGO
Perrigo
1.45
2.72
1.63
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.88
1.38

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.30%
Perrigo Company plc stock logo
PRGO
Perrigo
0.40%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510171.21 million126.36 millionOptionable
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2,89062.74 million60.04 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,100137.65 million137.10 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.65 million817.96 millionOptionable

Recent News About These Companies

Doctor Reddy's: Fiscal Q3 Earnings Snapshot
Dr. Reddy's Laboratories Ltd (RDY) Stock Forecasts

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.58 +1.10 (+5.10%)
Closing price 05/7/2026 03:59 PM Eastern
Extended Trading
$22.62 +0.04 (+0.19%)
As of 05/7/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$226.96 -1.61 (-0.70%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$226.96 0.00 (0.00%)
As of 05/7/2026 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Perrigo stock logo

Perrigo NYSE:PRGO

$11.74 -0.53 (-4.28%)
Closing price 05/7/2026 03:59 PM Eastern
Extended Trading
$11.77 +0.03 (+0.29%)
As of 05/7/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$13.44 -0.02 (-0.11%)
Closing price 05/7/2026 03:59 PM Eastern
Extended Trading
$13.42 -0.03 (-0.22%)
As of 05/7/2026 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.